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ABSTRACT
The small GTPase Rab25 has been functionally linked to tumour progression 
and aggressiveness in ovarian cancer and promotes invasion in three-dimensional 
environments. This type of migration has been shown to require the expression of 
the hypoxia-inducible factor 1 alpha (HIF-1α). In this report we demonstrate that 
Rab25 regulates HIF-1α protein expression in an oxygen independent manner in 
a panel of cancer cell lines. Regulation of HIF-1α protein expression by Rab25 did 
not require transcriptional upregulation, but was dependent on de novo protein 
synthesis through the Erbb2/ERK1/2 and p70S6K/mTOR pathways. Rab25 expression 
induced HIF-1 transcriptional activity, increased cisplatin resistance, and conferred 
intraperitoneal growth to the A2780 cell line in immunocompromised mice. Targeting 
HIF1 activity by silencing HIF-1β re-sensitised cells to cisplatin in vitro and reduced 
tumour formation of A2780-Rab25 expressing cells in vivo in a mouse ovarian 
peritoneal carcinomatosis model. Similar effects on cisplatin resistance in vitro and 
intraperitoneal tumourigenesis in vivo were obtained after HIF1b knockdown in the 
ovarian cancer cell line SKOV3, which expresses endogenous Rab25 and HIF-1α at 
atmospheric oxygen concentrations. Our results suggest that Rab25 tumourigenic 
potential and chemoresistance relies on HIF1 activity in aggressive and metastatic 
ovarian cancer. Targeting HIF-1 activity may potentially be effective either alone or 
in combination with standard chemotherapy for aggressive metastatic ovarian cancer.
INTRODUCTION
Ovarian cancer is one of the most lethal types of 
cancer and is the fifth most common cancer in developed 
countries [1]. The primary therapeutic regime for ovarian 
cancer patients involves surgical resection of the tumour 
followed by platinum based chemotherapy. Although the 
majority of patients respond to initial treatment, 70% of 
advanced stage patients will experience relapse, which 
is typically associated with more aggressive tumours, 
massive peritoneal dissemination and multi-drug 
resistance. Although many patients respond to second line 
treatment with gemcitabine and paclitaxel, there is still no 
effective therapy for platinum resistant tumours [2]. Thus, 
the problem of chemoresistance remains a high priority 
in this disease and the search for novel therapeutic targets 
continues.
In vitro studies and tumour sample analyses have 
identified a number of genes that associate with enhanced 
growth and invasiveness of ovarian cancer. One such 
gene is Rab25, a small GTPase of the Rab11 subfamily 
involved in endosomal recycling and trafficking pathways 
[3, 4] that is part of the RAS oncoprotein superfamily. 
Rab25 expression is upregulated in around 80% of ovarian 
cancer samples compared to normal ovarian epithelium, 
and increased Rab25 expression correlates with increasing 
tumour stage [3]. Enforced Rab25 expression in ovarian 
cancer cell lines results in increased cell proliferation, 
inhibition of apoptosis and anoikis and increased 
aggressiveness in vivo [5].
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Understanding the Rab25-mediated events that 
contribute to invasion, migration and metastatic progression 
could provide new targets for chemotherapeutic intervention.
Rapidly growing tumours outstrip their vascular 
supply and become hypoxic. Tumour cells that are able 
to survive in hypoxia exhibit an enhanced propensity to 
invade [6–8]. In hypoxic conditions, cells adapt to generate 
energy in oxygen independent ways and minimize cellular 
damage by inducing the expression of genes involved 
in angiogenesis, glycolysis, cell survival, invasion, 
tumour progression and pH regulation, which are mostly 
regulated by the hypoxia inducible factors (HIFs). HIFs 
are heterodimers having a constitutively expressed HIF-
1β subunit and an oxygen responsive HIF-α subunit [9] 
which is hydroxylated by prolyl hydroxylase (PHD) 
enzymes in an oxygen-dependent reaction. This triggers its 
ubiquitination by the E3 ubiquitin ligase von Hippel-Lindau 
protein (VHL), which targets HIF-α for 26S proteasomal 
degradation [10]. In hypoxic conditions, HIF-α escapes 
degradation, migrates to the nucleus, binds to HIF-1β and 
stimulates HIF-1 target gene expression [11].
Ovarian cancer generally metastasizes through 
direct dissemination from the primary site into the 
peritoneal cavity, without intravasation and extravasation 
of blood vessels [12]. Elevated levels of nuclear HIF-1α 
are associated with poor prognosis in ovarian malignancy 
and have been proposed as independent prognostic 
biomarkers [13, 14]. Furthermore, HIF-1α protein is 
overexpressed in the majority of non-hypoxic metastatic 
tumours [15] and its expression is associated with 
chemoresistance [16–18]. At present, our understanding 
of the mechanisms and consequences of HIF-1α induction 
in non-hypoxic tumours is limited. Rab25 expression in 
A2780 cells was shown to increase their tumourigenic 
potential in the peritoneum of immunocompromised mice 
[19], while SKOV3 cells expressing endogenous Rab25 
formed tumours in the peritoneal cavity of nude mice and 
exhibited elevated levels of HIF-1α expression under non-
hypoxic conditions [20]. Based on these observations, we 
aimed to elucidate the role of HIF-1α in mediating the 
association between Rab25 expression and the aggressive 
and tumourigenic phenotype of ovarian cancer cells.
RESULTS
Rab25 expression induces HIF-1α expression at 
atmospheric oxygen concentrations
To investigate whether Rab25 expression in the 
ovarian cancer cell line A2780 induces HIF-1α expression, 
stable cell lines expressing either pcDNA3 (DNA3) or a 
pcDNA3-Rab25 (Rab25) constructs were generated. After 
selection, cell extracts of different clones were analysed by 
Western blot for Rab25 and HIF-1α expression. All clones 
expressing Rab25 exhibited increased HIF-1α protein 
levels at atmospheric oxygen concentrations (Figure 1a, 
Supplementary Figure S1). Having selected Rab25 clone 
1 and DNA3 clone 2 for the remainder of the experiments, 
we demonstrated that nuclear HIF-1α expression was 
increased in Rab25 expressing cells compared to controls 
(Figure 1b). To ensure that these effects were not a result 
of stable cell line generation or specific to ovarian cells, 
transient transfections were performed in the A2780 cell 
line as well as the glioblastoma cell line U251 and the lung 
adenocarcinoma cell line A549. In normoxic conditions, 
levels of HIF-1α protein were significantly increased after 
transient transfection of Rab25 in all three cell lines (Figure 
1c). These results confirm that the effect of Rab25 on HIF-
1α expression is a general phenomenon shared by many 
cancer cell types and is oxygen-independent.
During these experiments it was noted that Rab25 
expression produced a morphological change in A2780 
cells, in which an increase in cell diameter was observed 
(data not shown). To exclude the potentially confounding 
effect of increased cell volume, cell extracts prepared 
using equal numbers of either A2780-pcDNA3 or A2780-
Rab25 cells were analysed and increased HIF-1α protein 
expression in Rab25 cell extracts observed as before.
HIF-1α nuclear localisation and HIF-1 
transcriptional activity is observed in Rab25-
expressing cells
To determine the cellular localisation of HIF-
1α in A2780-Rab25 expressing cells, cytoplasmic and 
nuclear extracts were prepared from A2780-Rab25 cells 
and analysed by Western blot. While increased HIF-1α 
protein levels were observed in both cytoplasmic and 
nuclear fractions of Rab25 cells compared to controls, 
relative HIF-1α levels were higher in the cytoplasm than 
the nucleus in both cell populations and nuclear HIF-1α 
levels were very low in DNA3 cells (Figure 2a). The 
purity of the fractionated extracts was verified by tubulin 
immunoblotting.
To investigate HIF-1α transcriptional activity, we 
analysed the HIF-1 downstream targets vascular endothelial 
growth factor (VEGF) and vimentin by Western blot. 
Increased protein levels of both VEGF and vimentin were 
detected in A2780-Rab25 expressing cells compared to 
empty vector (Figure 2b). ELISA revealed induction of 
VEGF to be significantly increased in all Rab25 clones 
compared with A2780-DNA3 clone 1 and in Rab25 clones 
1, 3 and 5 compared with A2780-DNA3 clone 2 (Figure 
2c and Table 1 ). HIF-1 luciferase reporter assays provided 
further confirmation of HIF-1 transcriptional activation by 
Rab25. In these experiments, A2780 cells were transiently 
co-transfected with empty vector or Rab25 in the presence 
of a HIF-1 luciferase reporter vector in which luciferase 
expression is driven by a HIF-1-dependent hypoxia-
response element cloned upstream of a minimal TATA 
box promoter. A three-fold induction in luciferase activity 
was observed upon Rab25 expression compared to empty 
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vector (DNA3) under non-hypoxic conditions (Figure 2d). 
Chromatin immunoprecipitation assays further validated 
these results, showing significantly increased binding of 
HIF-1α and the RNA Polymerase II-specific transcription 
factor TFIIB to the HIF-1 target gene glut1 promoter in 
Rab25-expressing cells compared to DNA3 cells (Figures 
2e and 2f). This result is specific since HIF-1α binding to 
the U1 gene promoter, which lacks HIF-1 binding regions, 
was not observed.
HIF-1 induces the expression of glucose transporters 
and enzymes involved in glycolysis, increasing the rate 
of glycolysis in cells and producing excess pyruvate, 
Figure 1: Rab25 induces HIF-1α expression in an oxygen-independent manner. a, b. Stable cell lines expressing either pcDNA3 
(DNA3) or a pcDNA3-Rab25 (Rab25) construct were generated in the ovarian cancer cell line A2780. After selection, the clones were analyzed 
by Western blot for Rab25 and HIF-1α expression. Clones expressing Rab25 exhibit higher levels of HIF-1α protein, both in cell extracts (a) and 
nuclear extracts (b). Clones number 1 for Rab25 and 2 for control cells were selected for the remaining experiments. Bars in graph (b) represent 
means with standard deviation of gels densitometric quantification (ImageJ) normalized to A2780-DNA3 HIF-1α expression of five independent 
experiments. Statistically significant as analysed by unpaired t-test. c. A2780, U251 and A549 cell lines were transiently transfected with 2μg 
of either pcDNA3 or pcDNA3-Rab25. 48 hours after transfection, protein cell extraction was performed and analyzed by Western blot for HIF-
1α and Rab25 expression. Actin is used as loading control. Graph depicts means with standard deviation of gels densitometric quantification 
(ImageJ) normalized to A2780-DNA3 HIF-1α expression of three independent experiments. Statistically significant as analysed by unpaired 
t-test. d. Western blot analysis for HIF-1α expression from extracts produced using equal number of cells (1x107) of either stable A2780DNA3 or 
A2780Rab25 cell lines. Graph depicts means with standard deviation of gels densitometric quantification (ImageJ) normalized to A2780-DNA3 
HIF-1α expression of three independent experiments. Statistically significant as analysed by unpaired t-test.
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Figure 2: Nuclear localization of HIF-1α and induction of HIF-1 transcriptional activity following Rab25 expression. a. Cytoplasmic 
and nuclear extracts (following Dignam protocol [51]) were analyzed by Western blot for HIF-1α expression. Tubulin was used as control for nuclear 
extract purity. Actin is the loading control. Graph depicts means with standard deviation of gels densitometric quantification (ImageJ) normalized to 
A2780-DNA3 HIF-1α expression of three independent experiments. Statistically significant as analysed by unpaired t-test. b. Whole cell extracts were 
analyzed by Western blot for VEGF and vimentin expression. Tubulin was used as control for nuclear extract purity. Actin is the loading control. c. 
Determination of secreted VEGF by Elisa assay of media recovered from A2780-DNA3 clones 1 and 2 (C1 and C2) and A2780-Rab25 clones 1 to 5 (C1 
to C5). Data presented represents means ± SEM from three independent experiments performed in duplicate. d. A2780 cells were transiently transfected 
with empty vector or Rab25 vector in the presence of a HIF-1 luciferase (HIF1Luc) reporter and analyzed 48 hrs after transfection for luciferase activity 
using a Xenogen IVIS 50 following addition of luciferin. No differences in cell number were observed following transfection of either pcDNA3 or 
pcDNA-Rab25 vectors. Data are presented as means ± SEM of triplicates. For statistical significance see Table 1. e. Chromatin immunoprecipitation assays 
performed on A2780-DNA3 or A2780-Rab25 stable cell lines showing increased binding of HIF-1α and the RNA Polymerase II-specific transcription 
factor TFIIB to the promoter of the HIF-1 target gene Glut-1 in the Rab25-expressing cells compared to control (DNA3). f. Graph representing means 
± SD of three independent of gels densitometric quantification (ImageJ) normalized to A2780-DNA3 glut1. P= statistical significance as analysed by 
unpaired t-test. g. A2780 cells stably expressing either Rab25 or DNA3 were grown for 24 hrs. Media was recovered and tested using BioVision Lactate 
Assay Kit II, and cells were trypsinized and counted to normalize values against cell number. Lactate concentration is normalized to 1x105 cells per 
experiment. Data represent mean ± SEM from three independent experiments, each performed in triplicate.
Oncotarget22654www.impactjournals.com/oncotarget
which is largely converted to lactate [21]. To determine 
whether Rab25 expression produced such a metabolic 
shift, we measured lactate production in our stable cell 
lines. As expected, lactate levels were increased in A2780-
Rab25 showed increased levels of lactate compared to 
control cells (Figure 2g). Overall, our results demonstrate 
increased HIF-1 activity following Rab25 expression.
Rab25 expression regulates HIF-1α protein 
levels through translational activation
HIF-1α expression can be regulated transcriptionally, 
translationally and/or through post-translational events 
(e.g. protein stabilisation). Similar levels of HIF-1α 
mRNA were detected in A2780-Rab25 and DNA3 cells, 
demonstrating no transcriptional upregulation (Figure 
3a). To confirm these observations, cells were treated 
with a-amanitin at a concentration which specifically 
blocks transcription of RNA polymerase II (2mgml-1). 
In Rab25 cells, mRNA levels of HIF-1α declined after 
a-amanitin treatment whereas the 18S rRNA transcript 
transcribed by RNA Polymerase I remained at a steady 
level and an increase in HIF-1α protein was observed 
(Figure 3b). This effect on HIF-1α was replicated in the 
low expressing A2780-DNA3 cells, in which a-amanitin 
treatment induced HIF-1α protein expression (Figure 
3c). Consistent with previous reports that transcription 
inhibitors such as a-amanitin activate the mTOR signalling 
pathway [22], activation of the downstream mTOR target 
p70S6K following a-amanitin treatment was detected in 
our cell lines (Figures 3b and 3c). These data indicate 
that activation of the mTOR/p70S6K pathway might be 
sufficient to enhance HIF-1α protein levels in the A2780 
cell line at normal oxygen concentrations. Because Rab25 
can activate mTOR/p70S6K [23], we compared activation 
of p70S6K in A2780 cells expressing either Rab25 or 
empty vector (DNA3). Increased p70S6K phosphorylation 
was observed in Rab25 cells compared to controls (Figure 
3d), and this was suppressed following mTOR inhibition 
with rapamycin (Figure 3e). Selective inhibition of 
mTOR also resulted in a reduction of HIF-1α protein 
levels in A2780-Rab25 overexpressing cells (Figure 3e), 
confirming our previous observations. Taken together, our 
results demonstrate a role for the mTOR/p70S6K pathway 
in mediating Rab25 regulation of HIF-1α expression.
ERK1/2 signalling has also been implicated in the 
translational and post-translational control of HIF-1α 
[24–26], through inhibition of protein degradation in an 
oxygen-independent manner [27]. Consistent with this, 
increased ERK1/2 activation was observed in Rab25 cells 
compared to control (Figure 3d). To determine if ERK is 
involved in Rab25 mediated induction of HIF-1α, protein 
extracts from cells treated with the specific MEK inhibitor 
UO126 were analysed by Western blot. U0126 treatment 
of A2780-Rab25 cells resulted in complete suppression of 
ERK1/2 phosphorylation and a corresponding reduction 
of HIF-1α protein to almost undetectable levels (Figure 
3f). Similar effects on HIF-1α levels were obtained 
using the MEK inhibitor PD98059, although to a lesser 
extent than UO126 (data not shown). While crosstalk 
between ERK signalling and p70S6K has been previously 
reported [28], we did not observe any changes in p70S6K 
phosphorylation after ERK inhibition (Figure 3f, lower 
panels), indicating that HIF-1α regulation by the ERK 
pathway is mTOR/p70S6K-independent.
ERK1/2 can also regulate HIF-1α post-
translationally by inhibition of ubiquitin-dependent 
proteasomal degradation [29–32]. To assess post-
translational regulation of HIF-1α by Rab25, the 
kinetics of HIF-1α protein decay were investigated 
following treatment with the protein synthesis inhibitor 
cycloheximide (CHX). Treatment with CHX resulted in 
a 50% reduction of HIF-1α protein levels after 15 min 
and complete disappearance after 60 min (Figure 3g). To 
confirm a translational induction of HIF-1α by Rab25, we 
hypothesized that inhibition of protein degradation would 
cause HIF-1α accumulation only in Rab25 cells, with little 
or no effect on DNA3 control cells. Consistent with this 
hypothesis, treatment with the proteasome inhibitor MG-
132 (1 μM) resulted in accumulation of HIF-1α in Rab25 
cells as predicted, whereas no increase in HIF-1α was 
detected in DNA3 cells (Figure 3h). These results indicate 
that Rab25 expression does not control the degradation 
and protein stability HIF-1α, but induces its translation.
Table 1: Increased VEGF levels are observed in Rab25 expressing cells compared to control
VEGF Elisa p values p values
C1 vs R1 0.0008 C2 vs R1 0.0051
C1 vs R2 0.0827 C2 vs R2 0.1839
C1 vs R3 0.0017 C2 vs R3 0.0109
C1 vs R4 0.013 C2 vs R4 0.1175
C1 vs R5 <0.0001 C2 vs R5 0.0023
Statistical significance as analysed by unpaired t-test calculated from three independent experiments, each performed in 
duplicate. C1 and C2 represent A2780-DNA3 clone 1 and A2780-DNA3 clone 2; R1 to R5 represent 5 different A2780-
Rab25 clones.
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Figure 3: Rab25 induces HIF-1α protein through a translational mechanism. a. HIF-1α transcript levels were determined by qRT-PCR 
analysis from mRNA extracts prepared from A2780DNA3 or A2780Rab25 cells. 18S rRNA levels were used as an internal normalization control. 
Data are presented as means ± SEM of triplicates from three independent experiments. b, c. A2780Rab25 cells (b) or A2780-DNA3 (DNA3) cells (c) 
were treated with either vehicle (DMSO) or a-amanitin (2μg/ml) for 24 hours. mRNA (b and c) and protein (b) were extracted following treatment. 
mRNA was analyzed by qRT-PCR for HIF-1α (upper panel). 28S rRNA was used as loading control. Protein extracts were analysed by Western blot 
for HIF-1α, phospho-Akt, phospho- and total-p70S6K. Actin served as loading control. d. Western blot analysis of protein extracts prepared from 
A2780DNA3 and A2780Rab25 stable cells comparing levels of HIF-1α, ERK1/2 (phosphorylated and total), and p70S6K (phosphorylated and total). 
e. mRNA and protein extracts from A2780-Rab25 (Rab25) cells were treated with rapamycin (10nM) for 24 hours and analysed by qRT-PCR and 
Western blot as in B. F. A2780Rab25 stable cells were treated with the MEK inhibitor U0126 (10μM) and protein extracts were prepared at different 
time points and analysed by Western blot. g. Protein translation was inhibited by cycloheximide (100μg/ml) and protein extracts were prepared at the 
indicated time points and analyzed by immunoblotting. h. Protein degradation was inhibited by MG-132 (1 μg/ml) and protein extracts were prepared 
at the indicated time points and analyzed by immunoblotting. i. Analysis of Erbb2 expression from a panel of cell lines: A2780DNA and A2780Rab25 
cell lines and SKOV3, A549 and U251 cells transiently transfected with pcDNA3 or pcDNA3-Rab25. Graph depicts means with standard deviation of 
gels densitometric quantification (ImageJ) normalized to A2780-DNA3 HIF-1α expression of three independent experiments. Statistically significant 
as analysed by unpaired t-test. j. HIF-1α expression analysis in A2780Rab25 cells following Herceptin treatment for 24 hours.
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The ERK and mTOR/p70S6K signalling pathways 
respond to activation of a variety of tyrosine kinase 
receptors one of which is ErbB2 [33–35]. In breast cancer 
patients, amplification and/or overexpression of ErbB2 
is strongly associated with worse prognosis and a higher 
incidence of metastases [36, 37]. Expression of Rab25 
was associated with significant increases in ErbB2 protein 
levels in a panel of difference cancer cell lines including 
A2780, SKOV3, A549 and U251 cell lines (Figure 3i). The 
observation that HIF-1α protein levels were significantly 
reduced in Rab25 cells treated with trastuzumab, a 
monoclonal antibody targeting ErbB2, indicates that HIF-
1α induction by Rab25 appears to be regulated by ErbB2 
as well as Erk1/2 and mTOR signalling pathways.
Rab25-induced epithelial to mesenchymal 
phenotype requires HIF-1 activity
VHL-silenced renal carcinoma cells take on an 
elongated, fibroblastoid morphology while VHL(+) 
cells grow as clusters of cuboidal and rhomboid cells. 
This phenotypical change from cuboidal (epithelial) 
to fibroblastoid (mesenchymal) morphology has been 
termed ‘epithelial to mesenchymal transition’, and 
requires HIF-1α activation [38]. Expression of Rab25 
in intestinal cells triggers the same EMT phenotype as 
VHL-silenced cells [39]. We observed a similar effect of 
Rab25 expression on cellular morphology of A2780 cells 
with flat, cuboidal DNA3 cells adopting an elongated, 
fibroblastoid morphology when expressing Rab25 (Figure 
4a). In order to interrogate the importance of HIF1 activity 
on the phenotypical changes associated with Rab25 
expression, A2780Rab25 cells were transduced with a 
lentivirus construct containing a short-hairpin (sh) RNA 
targeting HIF1β . Trasduction with this lentiviral construct 
has previously been demonstrated to stably inhibit HIF-1 
transcriptional activity [40]. By targeting the ubiquitously 
expressed HIF-1β subunit, HIF1 activity is inhibited 
irrespective of oxygen conditions and/or HIF-a subunit 
expression, making this approach a more robust method 
by which to abolish HIF-regulated gene expression. 
Following stable cell line selection, A2780Rab25-
shHIF1β cells exhibited a statistically significant 76.6% 
reduction in HIF-1β protein expression compared to 
A2780-Rab25 cells stably expressing scrambled shRNAs 
(A2780Rab25shScr, Figure 4b and 4c). HIF1α expression 
levels remained unchanged in both cell lines (Figure 4b). 
Whereas the elongated phenotype persisted in A2780-
Rab25shScr cells, HIF-1β knockdown caused this 
elongated morphology to revert to the cuboidal phenotype 
of the parental cells (Figure 4e). Consistent with previous 
observations that vimentin expression is associated with 
EMT, as well as being a HIF-1 target gene [41], HIF-
1β depletion was shown to reduce vimentin expression 
in A2780-Rab25-shHIF-1β compared to control (Scr) 
cells (Figure 4b). These data provide evidence that HIF-
1 transcriptional activity regulates the EMT program 
in the ovarian cancer cell line A2780 following Rab25 
expression.
Rab25 induced cisplatin resistance is HIF-1-
dependent
Rab25 was initially identified in a series of ovarian 
cancers that did not respond to chemotherapy [5] and 
subsequently shown to prevent apoptosis and anoikis 
induced by taxol-based chemotherapy. In line with these 
observations, Rab25 expression significantly increased 
cisplatin resistance of A2780 cells compared to controls 
(p=0.0014, calculated by Two-way ANOVA), as measured 
by cell viability assay (Table 2 and Figure 4d).
HIF-1α expression is also known to induce 
chemoresistance in cancer cells. To assess the role of 
HIF-1 activity in the resistance conferred by Rab25 
expression, cisplatin sensitivity was determined by 
MTT assay in Rab25shHIF-1β, shScramble-Rab25 
and SKOV3 ovarian cancer cells. SKOV3 cells, which 
express similar endogenous levels of HIF-1α to A2780-
Rab25 overexpressing cells (Figure 4f), were transduced 
as previously described with a lentivirus encoding shHIF-
1β to generate stable cell lines in which HIF-1β protein 
expression was reduced by 80.3% (Figures 4g and 4h). 
Consistent with our previous findings, HIF-1α expression 
levels were unchanged after knock-down of HIF-1β 
(Figure 4g). HIF-1β knock-down resulted in statistically 
significant sensitisation of A2780-Rab25 and SKOV3 
cells to cisplatin compared to shScramble control cells 
(p=0.0014 for A2780 Rab25-shScramble vs A2780 
Rab25-shHIF1b, and p=0.009 for SKOV3-shScramble vs 
SKOV3-shHIF1b, as calculated by 2way ANOVA), with 
~50% reduction in cisplatin IC50 values (Figure 4d and 
i, Table 2 ). HIF-1β knock-down reversed the cisplatin 
resistance conferred by Rab25 expression in A2780 
cells to similar levels observed in A2780-DNA3 cells, 
(Figure 4d and Table 2 ). These results indicate that the 
chemoresistance imposed by Rab25 expression correlates 
with HIF-1 activation.
Inhibition of HIF-1 activity reduces Rab25-
associated intraperitoneal tumourigenicity of 
ovarian cancer cells
To assess the tumourigenic potential of our cell 
lines, an ovarian peritoneal carcinomatosis mouse 
model was developed by injecting either A2780-
Rab25 or A2780-DNA3 cells in the peritoneal cavity of 
athymic nude mice (MF1 nu/nu). Tumour growth was 
monitored by non-invasive bioluminescent imaging after 
intraperitoneal injection of cells stably expressing firefly 
luciferase. As previously reported [5], 100% of the mice 
injected with A2780-Rab25 cells developed peritoneal 
disease compared to 25% of mice injected with A2780-
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Figure 4: Epithelial to mesenchymal transition and cisplatin resistance is HIF-1 dependent. a. Representative bright field images 
of A2780-DNA3 and A2780-Rab25 cells in culture. b. Cell extracts prepared from A2780Rab25-shScr or A2780Rab25-shHIF1β stable cell lines 
were analysed for protein expression levels for HIF-1β, HIF-1α, vimentin and Rab25 by Western blot. Actin served as loading control. HIF-1β 
expression levels were calculated from three independent experiments and percentage knockdown was calculated using densitometric quantification 
using densitometric quantification. The fraction of the average is presented. c. Graph representing means with standard deviation of gels densitometric 
quantification (ImageJ) normalized to A2780-shScramble HIF-1β expression of three independent experiments. P= statistical significance as analysed 
by unpaired t-test. d. Cell viability assays following cisplatin treatment at a concentration range. Means of three independent experiments for each cell 
line are presented (error bars represent ±SEM). e. Representative bright field images of A2780Rab25-shHIF1β and A2780Rab25-shScr cells. For the 
generation of A2780-Rab25 cells expressing shRNAs, cells were transduced with a lentiviral construct expressing either shScramble (shScr) or shHIF-
1β RNA and selected with puromycin. f. Comparison of HIF-1α protein expression in A2780-Rab25 and SKOV3 cell lines by Western blot. g. HIF-1β 
expression levels in SKOV3-shHIF1β and SKOV3-shScr cell lines, along with unchanged HIF-1α expression levels and actin as loading control. 
h. Each sample in G was repeated thrice and percentage knock-down was calculated using densitometric quantification. i. Cell viability assays following 
cisplatin treatment at a concentration range. Means of three independent experiments for each cell line are presented (error bars represent ±SEM).
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DNA3 cells (Figure 5a and Table 3 ). In comparison, no 
difference in tumorigenicity was observed in two cohorts 
(n = 6 mice) injected subcutaneously with either Rab25 
or DNA3 expressing cells, (data not shown). Since 
Rab25 intraperitoneal xenografts harvested five weeks 
after inculation exhibited higher levels of HIF-1α and 
VEGF expression than A2780-DNA3 tumours (Figure 
5b), the effect of HIF-1 activity on tumorigenicity and 
invasiveness was investigated by injecting luciferase 
expressing A2780Rab25-shHIF-1β and SKOV3-shHIF1β 
cells intraperitoneally as described above. Luminescence 
was detected in four out of nine mice in the A2780Rab25-
shHIF1β cohort at week 5 (Figure 5c and Table 3 ), in 
two of which the signal was comparable to that of A2780-
Rab25 and A2780-Rab25shScr tumours. In the remaining 
two mice, luminescence was weak at week 5, and no 
visible tumour was apparent on internal examination of 
the peritoneum (Figure 5c, Table 3 ). In contrast, strong 
luminescence was detected in all mice injected with 
A2780Rab25-shScr cells, and tumours disseminated 
throughout the peritoneal cavity were observed on internal 
examination (Figure 5c and Table 3 ).
Recently, HIF-1α has been shown to be essential 
for the maintenance of ‘tumour initiating’ or ‘cancer stem 
cells’ (CSCs) in various cancer types [42–44]. Based on 
our previous data, which support this hypothesis in the 
context of ovarian cancer, tumour sphere assays were 
performed using the panel of ovarian cancer cell lines 
described above. In this assay, tumour spheres are grown 
in anchorage-independent and serum-free conditions can 
be used as an in vitro surrogate of tumourigenicity. The 
resulting spheres are enriched in cancer stem-like cells and 
are capable of serial propagation of their original tumour 
phenotype in animals [45]. Rab25 expressing cells formed 
significantly more spheres than the control cell line A2780-
DNA3 (Figure 5d), and although a modest decrease in 
sphere-forming efficiency was observed in cells transduced 
with shScramble lentivirus, which might be attributable 
to the dual antibiotic selection required, HIF-1β knock-
down significantly reduced the number of spheres formed 
compared to either Rab25shScramble or Rab25 expressing 
cells (Figure 5d). Taken together, our results demonstrate 
that HIF-1 activity is required for both maintenance of CSC 
phenotype in A2780 cells and their tumourigenicity in vivo.
To exclude the possibility that the HIF-1 requirement 
for A2780-Rab25 tumourigenicity is specific to this cell line, 
a second ovarian peritoneal mouse model was developed 
using the SKOV3 cell line, which expresses endogenous 
Rab25 and HIF-1α at atmospheric oxygen concentrations. 
100% of mice injected with SKOV3 cells developed 
tumours in the peritoneal cavity (Table 3). In order to 
investigate HIF-1 dependency of SKOV3 tumourigenicity, 
three cohorts of mice were injected with either SKOV3-
shHIF-1β clone 1 (SKOV3-shHIF-1β), SKOV3-shHIF-
1β clone 2 (SKOV3-shHIF-1β-2) or SKOV3-shScr. 
Although HIF-1β knock-down did not reduce SKOV3 
tumourigenicity (Table 3), it had an impact on tumour 
burden as indicated by the significantly reduced luminescent 
signal obtained from SKOV3-shHIF-1 tumours compared 
with those derived from SKOV3-shScr cells (Figure 5e). 
Protein was extracted from tumours formed by SKOV3-
shHIF1β and SKOV3-shScr and analysed for HIF-1β 
expression by Western blot. The percentage knock-down 
seen in SKOV3-shHIF-1β tumours (56.1%, 75.04% and 
41.08%, Figure 5f) was lower than that seen in cells grown 
in culture for the same period of time (80.6% knock down, 
Figure 4e). This re-expression of HIF-1β in vivo might 
explain why there was no change in tumourigenicity.
DISCUSSION
This study aimed to determine the role of HIF-1 
in the invasive and metastatic ovarian cancer phenotype 
associated with expression of the small GTPase protein 
Rab25. Induction of HIF-1α was observed upon expression 
of Rab25 across a panel of cancer cell lines of different 
origins. HIF-1α induction occurred in parallel with a 
variety of tumour responses including EMT, metabolic 
reprogramming, chemoresistance and was strongly 
associated with increased peritoneal tumourigenicity in 
nude mice. All these effects were reversed upon HIF-1 
transcriptional inactivation through HIF-1β knock-down. 
Rab25 increased HIF-1α expression through an Erbb2 and 
ERK1/2 and p70S6K/mTOR dependent mechanism in an 
Table 2: In vitro cytotoxicity of free cisplatin in the human ovarian cancer cell line A2780 expressing empty vector 
(DNA3), Rab25, Rab25 and scramble short-hairpin (shScr) or Rab25 and shHIF1β 
IC
50
 for Cisplatin (95%CI), μM
A2780DNA3 0.0387 (0.03006-0.05004)
A2780Rab25 0.5737 (0.3944-0.8344)
A2780Rab25-shScr 2.223 (1.782-2.772)
A2780Rab25-shHIF1β 0.1235 (0.1043-0.1463)
SKOV3-shScr 3.49 (2.677-3.879)
SKOV3-shHIF1β 1.65 (1.111-1.915)
As assessed by cell viability assay (MTT). IC50 calculated from three independent experiments.
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Figure 5: In vivo tumorigenic potential of A2780-Rab25 and SKOV3 cells is HIF1-dependent. a. Representative images of mice injected 
i.p. with 5x106 of A2780, A2780-Rab25 or SKOV3 cells stably expressing luciferase and monitored over time by measuring luciferase expression after 
s.c. administration of luciferin (30mg/ml) using an IVIS-50 imaging system. b. HIF-1α and VEGF immunohistochemistry images of lung, intraperitoneal 
(i.p.) or subcutaneous (s.c.) tumours taken from mice at 28 days after inoculation. c. Longitudinal studies of i.p. tumours from mice injected with 5x106 
of A2780Rab25-shHIF1β or A2780Rab25-shScr cells. Mice were monitored once a week for five weeks by bioluminescence. d. Sphere formation 
assay in A2780-DNA3, A2780-Rab25, A2780-Rab25shScr and A2780-Rab25shHIF-1β. Each experiment was repeated thrice and error bars represent 
SEM; *p<0.005. e. Longitudinal studies of i.p. tumours from mice injected i.p. with SKOV3-shHIF1β1 and SKOV3-shHIF1β2 compared to SKOV3-
shscramble-Lluc. Each cell line was intraperitoneally injected into six nude mice and tumours were monitored for 4 weeks through luminescence (Total 
flux). Graph depicts means of six mice per cohort, error bars represent SEM. Statistical significance calculated for each SKOV3-shHIF-1β vs control 
cell line SKOV3-shScramble using two-way ANOVA. f. Western blot for HIF1β expression in tumour samples obtained from three mice (M1 to M3) 
injected with either SKOV3-shHIF1β1 (shHIF1β) or SKOV3-shScr cells (shScr) for 4 weeks. Actin served as loading control. Graph representing 
HIF1β knock-down normalised protein levels obtained by densitometric quantification of bands from extracts of three independent SKOV3-shHIF-1β 
tumours and compared HIF1β levels from SKOV3-shScramble tumours. Three independent SKOV3-shScramble tumours were analysed and averaged.
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oxygen-independent manner. To our knowledge, this study 
is the first to show upregulation of HIF-1α via ErbB2. Rab 
GTPases are critical for mediating signalling transduction 
propagation from growth factors via the regulation of their 
intracellular localisation. A role for Rab25 in regulating 
epidermal growth factor receptor (EGFR) trafficking has 
been previously reported [46]. Our novel observation 
that Rab25 might also be involved in Erbb2 regulation 
warrants further investigation.
It has been suggested that Rab25 promotes the cancer 
pathophysiological phenotype by regulating cellular ATP 
levels and glycogen stores that protect cancer cells from 
bioenergetic stress. For example, Rab25 has been shown 
to increase glucose uptake by binding and trafficking the 
HIF-1 target gene GLUT1 to the cytoplasmic membrane 
[47]. We report here increased binding of HIF-1 to the 
GLUT1 promoter following Rab25 expression. These 
data suggest that Rab25 is not only involved in regulating 
cellular localisation of GLUT1 but also its abundance at 
the transcriptional level. Such an effect on both cellular 
localisation and transcriptional control of GLUT1 by 
Rab25 has the ability to ensure cancer cell survival under 
nutrient stress conditions. HIF-1 activation also results in a 
large increase in glycogen stores [48]. Increased glycogen 
accumulation in Rab25-expressing cells has been observed 
both in vitro and in vivo in ovarian cancer patient tumour 
samples [48]. HIF-1 activation provides an additional 
mechanism by which Rab25 could produce glycogen 
accumulation. Our results help explain why these cells 
can metastasize and invade the peritoneum during acute 
bioenergetics stress. In addition, several HIF-1 targets 
can regulate peritoneal invasion in vivo. These include 
VEGF, MMP1 (matrix metallopeptidase 1) and 9, TGF-α 
(transforming growth factor α) and/or IGF-2 (insulin-like 
growth factor-2) [49]. The models that we have developed 
might help elucidate what target genes are essential for 
ovarian peritoneal carcinomatosis, allowing identification 
of novel therapeutic targets.
In conclusion, our results demonstrate that HIF1 is a 
major factor controlling the aggressive and chemotherapy-
resistant phenotype of Rab25 expressing ovarian cancers 
and indicate that targeting HIF-1 activity might be 
effective either alone or in combination with standard 
chemotherapy for aggressive metastatic ovarian cancer.
MATERIALS AND METHODS
Materials
Cisplatin, MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] were obtained from 
Sigma-Aldrich Co. Ltd (Dorset, UK). Luciferin was 
obtained from Caliper Lifesciences Ltd (Wellfield, UK). 
G418S Sulphate solution was obtained from ForMedium 
Ltd (UK). Blasticidin, Lipofectamine 2000, Virapower 
Promoterless Lentiviral Gateway Kit were obtained from 
Invitrogen Co. (Paisley, UK). Lactate was measured using 
BioVision Lactate Assay Kit II. VEGF was quantified by 
VEGF Elisa from Calbiochem. The following antibodies 
were used: Actin from Santa Cruz Biotechnology; Bak and 
Bax from Cell Signalling Technology; HIF-1α, HIF-1β 
and PARP from BD Transduction Laboratories; p53 from 
Leica Microsystems; and vimentin from Abcam.
Luciferase reporters
The luciferase reporter was constructed using the 
ViraPower Promoterless Lentiviral Gateway Expression 
System according to manufacturers’ instructions. It 
contains the luciferase gene controlled by the Ubiquitin 
C promoter. The luciferase gene was amplified from 
plasmid pGL4-CMVLuc (Promega) using the following 
primers: Forward-5′ CACCATGGAAGACGCCAAA; 
Reverse-5′ AAACACGGCGATCTTTCCG. The p53 
reporter was amplified from p53 Luciferase Reporter 
Vector (Panomics) using the following primers: 
Table 3: Tumorigenic potential of ovarian cancer cell lines A2780 and SKOV3 either scramble (Scr) or HIF-1β short 
hairpin RNAs
Cell line Tumour Incidence Percentage
A2780DNA3 2/8 25%
A2780Rab25 8/8 100%
A2780Rab25shScr1 8/8 100%
A2780Rab25shScr2 7/8 87%
A2780Rab25shHIF1β 2/9 22.22%
SKOV3 6/6 100%
SKOV3-shScr 6/6 100%
SKOV3-shHIF1β 6/6 100%
Mice were injected intraperitoneally with 5x106 cells and monitored for signs of disease (abdominal inflammation, weight 
loss). Experiment endpoint was at six weeks.
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Forward-5′ GGTACCGAGCTCTTA; Reverse-5′ GCT 
TTACCAACAC. All PCR reactions were carried out 
with Proofstart DNA Polymerase (Qiagen) following 
manufacturer’s protocols. Cloning of the luciferase 
product into pENTRTM-gene was done according to 
manufacturers’ instruction (VirapowerTM Promoterless 
Lentiviral Gateway® Kits). Cloning product was 
confirmed by sequencing with ABI PRISM 3130XL 
Genetic Analyzer (Applied Biosystems, Foster City, CA). 
Lentiviral construct was performed by recombination of 
the supplied plasmids pENTRTM5′/UbCp, containing the 
ubiquitin C promoter, pLenti6/R4R2/V5-DEST and the 
cloned pENTRTM-luciferase. Transfection was performed 
as described previously in HEK293T cells. Virus was 
harvested 72hr post transfection, filtered through 0.45μm 
filter (Millipore, Bedford, MA) and resuspended in fresh 
medium or array buffer. Titers of lentiviral preparations 
were determined using A2780 cells and were around 106 
IFU/ml. To infect cells using lentiviral vectors, cells were 
placed in a 6-well plate at a density of 5x107 million cells/
well the day before infection. The next day medium was 
removed and 2ml lentivirus in cell culture medium was 
added in the presence of 2μg/ml polybrene to initiate 
infection. Viruses were removed 24hr after infection 
and fresh cell culture medium was added. After 24 hr, 
blasticidin (2.5mg/ml) was added and selection performed 
for cells expressing luciferase.
Cell lines
The human ovarian carcinoma cell line A2780 
was obtained from Dr. R. F. Ozols (Fox Chase Cancer 
Centre, Pennsylvania, U.S.A.). The SKOV3 cell line was 
obtained from ATCC. Cells were maintained in Roswell 
Park Memorial Institute 1640 medium (Invitrogen) 
containing glutamine (2mM) and foetal calf serum (10%). 
The stable cell lines expressing Rab25 or empty vector 
were generated by selection of transfected cells with 
pcDNA3-Rab25 or pcDNA3 plasmid using Lipofectamine 
2000 according to manufacturers’ instructions. Once 
stables cells were selected and analysed for Rab25 
expression, they were transduced with a firefly luciferase 
reporter previously generated and clones were selected 
with blasticidin. Stable cell lines expressing Rab25 and 
luciferase were grown in the presence of geneticin (0.5mg/
ml) and blasticidin (2.5mg/ml). Cells were grown in the 
absence of drugs for 24 hours before in vivo experiments 
and for the duration of experiment for in vitro assays.
shRNA cloned in pLKO.1 vector (Reference code: 
TRCN0000003819 the TRC library, Open Biosystems, 
now under the Thermoscientific umbrella and the 
reference is http://www.broadinstitute.org/rnai/public/
clone/details?cloneId=TRCN0000003819) targeting 
HIF1β was used for knockdown in A2780Rab25-Lluc 
and SKOV3-Lluc using lentiviral gene delivery method. 
Lentivirus construct was made using Virapower 
promoterless Lentiviral Gateway kits (InvitrogenTM) 
according to manufacturer’s instructions using pLKO.1 
vector with shHIF1β as the pLenti-based expression 
plasmid. Non-targeting shRNA scramble was used 
as negative control. pLKO.1 plasmid has Puromycin 
resistance gene and RPMI with puromycin was used for 
selecting successfully transduced cells.
Protein extraction from tissue
Tissue was ground into a fine powder in liquid 
nitrogen and lysis buffer (0.5%NP40 (Sigma®), 250nM 
Sodium Chloride and 50mM HEPES pH7.0) supplemented 
with PIC (Roche) in 5:1 proportion was added to powder; 
and was incubated at room temperature for 15 min. Protein 
extract was obtained by centrifugation at 16100g for 
10min.
Cytotoxicity assay
Drug sensitivity was determined by tetrazolium 
based chemosensitivity assay as described previously 
[50]. Briefly, cells were plated out at a density of 1x103 per 
well in 96-well flat bottomed plates (IWAKI) and allowed 
to attach and grow for 2-3 days. They were exposed to 
cisplatin for 24 hr and then fed with fresh medium daily 
for 3 days. On the fourth day, cells were fed with medium 
containing HEPES buffer (10mM) and MTT (50mL, 5mg/
mL) was added to each well. Plates were incubated in the 
dark at 37°C for 4 hr, medium and MTT removed and the 
MTT-formazan crystals dissolved in dimethyl sulphoxide 
(200mL/well). Glycine buffer (25mL/well, 0.1M, pH 10.5) 
was added and the absorbance measured at 570nm in a 
multi-well plate reader (Model Emax, Molecular Devices 
Ltd., Wokingham UK).
For drug addition a serial dilution of eight 
concentrations of cisplatin was prepared. Four wells were 
used for each drug concentration. Cisplatin was solubilised 
in dimethyl sulphoxide before addition to medium with a 
final concentration of less than 1%.
Results are expressed in terms of the drug 
concentration required to kill 50% of the cells (IC50) 
estimated as the absorbance value equal to 50% of that of 
the control untreated wells.
Tumour growth in vivo
Cell lines A2780 and A2780-Rab25 were established 
as xenografts in six to eight-week-old athymic female nude 
(MF1 nu/nu) mice. Monolayer cultures were harvested 
with trypsin/EDTA and resuspended in PBS. Animals were 
housed in autoclaved microisolator cages in an air-filtered 
laminar flow cabinet and were given food and water ad 
libitum. All procedures were performed under sterile 
conditions in a laminar flow hood. This animal experiment 
was in compliance with all regulatory guidelines.
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For luminescence recording, mice were injected 
s.c. with 200ml of the D-luciferin substrate (30mg/
ml). Following injection, mice were anaesthetised with 
isoflurane (3% and 1 litre/min oxygen) and placed in the 
imaging system. Luminescence was recorded 10 min after 
luciferin injection with an exposure time of 1 min using 
the Xenogen IVIS50 imaging system from Caliper Life 
Sciences Ltd. (Wellfield, UK). Imaging was repeated 
weekly to allow estimation of tumour burden over time.
For i.p. xenografts, about 5x106 cells were injected 
into the peritoneal cavity of mice and mice were imaged 
on a weekly basis.
Analysis of the bioluminescent images was 
performed by defining a set region of interest to be used 
in all animals. For the disseminated model, the signal over 
the entire abdomen of the mouse was analysed.
Tumour sphere forming assay
Tumour sphere forming assay was performed as 
previously described with few modifications [44]. Cells 
were seeded at 100 cells per well in a 96-well plate and 
left for 7 days, replenishing with 25ml of serum-free 
medium every other day. Serum-free medium consisted of 
Ad/DMEM/F12 (Invitrogen, Paisley UK) supplemented 
with 10 U/ml heparin, 2% B27 (Invitrogen), human 
recombinant fibroblast growth factor 2 (FGF-2, 20 ng/ml, 
Sigma-Aldrich) and epidermal growth factor (EGF, 20 ng/
ml, Sigma-Aldrich). After 7 days, properly formed spheres 
were counted. The data calculated for the number of spheres 
is the average of three independent experiments. Spheres 
were counted from 32 different wells/cell line/experiment.
Statistical analysis
Experiment results obtained were statistically evaluated 
by simple t-test. Differences were considered significant if 
P<0.05. Statistical analysis was performed by SigmaPlot 10.0.
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